PositoAI/ US/ Denali Therapeutics Inc.

Denali Therapeutics Inc.

NasdaqGS: DNLI · Healthcare

Positivity Index

#4,796 / 6,775

Global

#2,481 / 3,999

United States

Positivity Score

18,999

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Denali Therapeutics Inc. — Overview & Financial Snapshot

Denali Therapeutics Inc. (NasdaqGS: DNLI) is a Healthcare company, ranked #4,796 of 6,775 companies globally and #2,481 of 3,999 in United States on PositoAI, with a Positivity Score of 18,999. Its market capitalisation is ₹27,892.41 Cr ($2.94B), P/E ratio is -6.5 and P/B ratio is 3.52. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #7 Impact BioMedical Inc. 26,324 #13 Onconetix, Inc. 25,899 #16 Revelation Biosciences, Inc. 25,763 #17 BioStem Technologies, Inc. 25,743

— Nothing to show —

OpenAI is reading recent news...

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

P/B Ratio 3.52

P/E Ratio -6.5

D/E Ratio 0.05

ROE -54.93%

Owes vs Owns ? 0.28× Low $0.28 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-269.18$-2.84

Forward EPS ₹-229.10$-2.42

Beta 1.02

Market Cap ₹27,892.41 Cr$2.94B

What these numbers mean →

What does Denali Therapeutics Inc. do?

What is Denali Therapeutics Inc.'s P/E and P/B ratio?

Denali Therapeutics Inc. has a P/E ratio of -6.5 and a P/B ratio of 3.52.

What is Denali Therapeutics Inc.'s debt-to-equity ratio?

Denali Therapeutics Inc. has a debt-to-equity ratio of 0.05.

How much does Denali Therapeutics Inc. owe compared with what it owns?

Denali Therapeutics Inc. owes $0.28 for every $1 it owns (balance sheet Jun 2026), which is low.

What is Denali Therapeutics Inc.'s Positivity rank?

Denali Therapeutics Inc. is ranked #4,796 of 6,775 companies globally and #2,481 of 3,999 in United States on PositoAI, with a Positivity Score of 18,999.

Does Denali Therapeutics Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Denali Therapeutics Inc..

Where can I read the latest news about Denali Therapeutics Inc.?

Recent headlines about Denali Therapeutics Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Denali Therapeutics Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Denali Therapeutics Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.